# Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

> **NCT01033097** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 80 (actual)

## Conditions studied

- Pruritus in Patients With Atopic Dermatitis

## Interventions

- **DRUG:** DNK333 5 mg
- **DRUG:** Placebo to 5 mg
- **DRUG:** DNK333 25 mg
- **DRUG:** Placebo to 25 mg
- **DRUG:** DNK333 100 mg
- **DRUG:** Placebo to 100 mg
- **DRUG:** Betamethasone 4 mg
- **DRUG:** DNK333 1mg
- **DRUG:** Placebo to 1mg

## Key facts

- **NCT ID:** NCT01033097
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033097, "Safety and Efficacy of DNK333 in Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01033097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*